Lauren D'Angelo

“I'm pleased to provide a detailed update on our Q1 2026 commercial performance. This was a quarter of meaningful execution across prescriber adoption, nursing home penetration and payer engagement and the data tell a compelling story of durable accelerating commercial traction.”

“The fourth quarter marked what we believe is an important inflection point in the U.S. launch of Zundale in long-term care. What we are seeing now is not just continued growth, it is accelerating durable adoption.”

“The third quarter reflected continued strong momentum in the U.S. rollout of ZUNVEYL within the long-term care market. Following a successful launch earlier this year, Q3 results show sustained acceleration in demand and prescriber adoption, reinforcing ZUNVEYL's growing role in Alzheimer's disease management.”

“The second quarter of 2025 marked a significant acceleration in our commercial rollout of ZUNVEYL in the U.S. long-term care market.”

“I'm pleased to provide an update on our commercial progress following the launch of ZUNVEYL, which is now available nationwide. We officially launched just over a month ago, and I'm excited to report that the early response from the market has been both encouraging and validating.”